Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc (INO) Option Chain
As of September 25, 2026, Inovio Pharmaceuticals Inc is trading at $1.18, a -2.48% change from the previous close. The nearest expiration is Oct 2, 2026. Implied volatility is 3,153.2%. IV Rank is 90%.
Read more
Tracking the INO option chain helps you see every strike and expiry on Inovio Pharmaceuticals Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Inovio Pharmaceuticals Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of INO options activity at a glance. Use our scanner to monitor the INO option chain in real time and filter for the INO options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For INO stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the INO option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where INO stock options are being actively traded and where they are not.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever.
Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Inovio Pharmaceuticals Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen INO options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of INO stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile90.48% Elevated
- Market cap (M$)122
- 52 weeks high-56.62%
- 52 weeks low110.71%
- Analyst recommendationBuy
1.67 - Target price$3.17
168.64% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-1.18
- EPS growth next 5 years61.91%
As of September 25, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 97.36 | 9 | 0 | 0.22 | 0.68 | 0.35 | 1.45 | 0.50 | -57.63 | — | 0.05 | 0.00 | 0.05 | 0 | 0 | 2.64 |
| 98.21 | 88 | 0 | 0.52 | 0.18 | — | 0.70 | 1.00 | -15.25 | — | 0.05 | 0.00 | 0.05 | 0 | 2 | 1.79 |
| 98.59 | 181 | 0 | 0.05 | 0.00 | — | 0.05 | 1.50 | +27.12 | — | 0.60 | 0.32 | 0.28 | 0 | 7 | 1.41 |
| 98.81 | 516 | 0 | 0.05 | 0.00 | — | 0.05 | 2.00 | +69.49 | — | 2.95 | 0.82 | 2.13 | 0 | 0 | 1.19 |
As of September 25, 2026
Scan the full option chain in one place
Browse the full INO option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→